1 Steps
Maximum: 2 CME cr.
Sign in to view your progression
Programme Background
Learning Objectives
Target Audience
Credit Designation

This educational activity consists of two modules focusing on prostate cancer (PCa) and the spectrum of disease states that it represents, as well as how its management must be tailored to individual patients. The first module is a roundtable discussion which reviews the latest evidence and updates to clinical practice guidelines in the optimal care of patients with advanced prostate cancer, through a case-based approach. The second module is an eSeries presentation in which the lead investigators of the LATITUDE and STAMPEDE trials give their expert insight on the latest results of clinical trials in patients with advanced PCa.

Estimated time to complete activity: 2.5 hours

Release date: March 22, 2018
Expiration date: March 22, 2020

After viewing this program, participants should be able to:

● Compare and contrast the results of the docetaxel studies from the GETUG, CHAARTED, and STAMPEDE trials

● Describe the efficacy and safety outcomes of the LATITUDE and STAMPEDE trials in patients with high-risk M0 PCa and those with newly diagnosed high-risk hormone-sensitive advanced PCa starting long-term ADT

● Discuss the expanding role of abiraterone acetate plus prednisolone/prednisone in the standard of care for advanced PCa based on the LATITUDE and STAMPEDE trial result

This program is designed for urologists, uro-oncologists, residents and urologists-in-training around the world who are SIU members or SIU Academy-registered members.

This program is accredited by the European Accreditation Council for Continuing Medical Education (EACCME). The credits for the users of the module will be 1 European CME credit (ECMEC®) for every hour (60 minutes of actual e-learning excluding introductions etc.) of use, provided that the users have completed a module and have passed the relevant assessment.

Program Scientific Committee & Disclosures

Karim Fizazi, MD, PhD
Disclosures: Participation to advisory boards/honorarium for: Amgen, Astellas, AstraZeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, Sanofi

Christopher P. Evans, MD, FACS
United States
Disclosures: Research support, speaker’s honoraria, consulting from Janssen, Astellas, Sanofi.

Nicholas James, MBBS, PhD
United Kingdom
Disclosures: Trial funding from: Cancer Research UK, Medical Research Council, Astellas, Janssen, Novartis, Pfizer, Sanofi-Aventis
Speaking fees and Advisory Boards: Astellas, Bayer, Janssen, Novartis, Pfizer, Sanofi-Aventis

Evolution of Treatment Pathways in the Advanced Prostate Cancer Continuum

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies